ReviewCancers2021
Podocalyxin in Normal Tissue and Epithelial Cancer.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 55 citations in OpenAlex.
- Keratan Sulfate: An Electroconductive Glycosaminoglycan at the Interface of Sensory Perception and Neural Signaling.Journal of neuroscience research · 2026Review
- Podocalyxin may be down-regulated by progesterone in high grade serous ovarian cancer spheroids to increase responsiveness to carboplatin and NK cells.BMC cancer · 2026Article
- Urinary vesicle biomarkers and kidney function-results from the German AugUR study.Scientific reports · 2026Article
- Structural and Dynamic Insights into Podocalyxin-Ezrin Interaction as a Target in Cancer Progression.Journal of xenobiotics · 2026Article
- Podocalyxin and ciliary neurotrophic factor receptor are novel components of the surfaceome of chondrogenic cells.Cell communication and signaling : CCS · 2025Article
- Podocalyxin, Isthmin-1, and Pentraxin-3 Immunoreactivities as Emerging Immunohistochemical Markers of Fibrosis in Chronic Hepatitis B.Biomedicines · 2025Article
- Podocalyxin protects high grade serous ovarian cancer spheroids from NK cell infiltration and spheroid destruction.BMC cancer · 2025Article
- Expression of vimentin intermediate filaments in epithelial cells promotes cell migration and cell matrix interaction in 3D.bioRxiv : the preprint server for biology · 2025Article
- A Cancer-Specific Anti-Podocalyxin Monoclonal Antibody (humPcMab-60) Demonstrated Antitumor Efficacy in Pancreatic and Colorectal Cancer Xenograft Models.Antibodies (Basel, Switzerland) · 2025Article
- Keratan Sulfate Is a Multifunctional Brain Glycosaminoglycan With Instructive Capabilities.Journal of neurochemistry · 2025Review
- A prognostic nomogram based on desmoplastic reaction/tumor deposit modified lymph node staging in colorectal cancer.Journal of gastrointestinal oncology · 2025Article
- Glycosaminoglycans, Instructive Biomolecules That Regulate Cellular Activity and Synaptic Neuronal Control of Specific Tissue Functional Properties.International journal of molecular sciences · 2025Review
- Identification and Validation of Key Biomarkers in the Proximal Aqueous Humor Outflow Pathway.Current issues in molecular biology · 2025Article
- Anti-Adhesive Podocalyxin Expression Is Disrupted in Recurrent Implantation Failure.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Article
- Towards the Identification of New Biomarkers in Saliva and Serum for Treatment Monitoring of Equine Gastric Ulcer Syndrome: A Liquid Proteomic Approach.Animals : an open access journal from MDPI · 2024Article
- Evaluating new biomarkers for diabetic nephropathy: Role of α2-macroglobulin, podocalyxin, α-L-fucosidase, retinol-binding protein-4, and cystatin C.World journal of diabetes · 2024Article
- The proteomic profile is altered but not repaired after bariatric surgery in type 2 diabetes pigs.Scientific reports · 2024Article
- Network analysis of the proteome and peptidome sheds light on human milk as a biological system.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Podocalyxin (PODXL), a glycosylated cell surface sialomucin of the CD34 family, is normally expressed in kidney podocytes, vascular endothelial cells, hematopoietic progenitors, mesothelium, as well as a subset of neurons. In the kidney, PODXL functions primarily as an antiadhesive molecule in podocyte epithelial cells, regulating adhesion and cell morphology, and playing an essential role in the development and function of the organ. Outside the kidney, PODXL plays subtle roles in tissue remodelling and development. Furthermore, many cancers, especially those that originated from the epithelium, have been reported to overexpress PODXL. Collective evidence suggests that PODXL overexpression is linked to poor prognosis, more aggressive tumour progression, unfavourable treatment outcomes, and possibly chemoresistance. This review summarises our current knowledge of PODXL in normal tissue function and epithelial cancer, with a particular focus on its underlying roles in cancer metastasis, likely involvement in chemoresistance, and potential use as a diagnostic and prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.